All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 2: Cardiovascular
Toggle Pages
Print this page
Management of atrial fibrillation
Drugs that prolong the QT interval
Anticoagulation prescribing guidance
Management of suspected deep vein thrombosis (DVT) and pulmonary embolism (PE)
Secondary prevention of stroke / TIA in primary care
Management of angina
Chronic heart failure guidance
Management of hypertension
Management of blood lipids
2.1 Positive inotropic drugs
2.2 Diuretics
2.3 Anti-arrhythmic drugs
2.4 Beta-adrenoceptor blocking drugs
2.5 Hypertension and heart failure
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs
2.7 Sympathomimetics
2.8 Anticoagulants and protamine
2.9 Antiplatelet drugs
2.10 Stable angina, acute coronary syndromes, and fibrinolysis
2.11 Antifibrinolytic drugs and haemostatics
2.12 Lipid regulating drugs
2.13 Local sclerosants
2.14 Miscellaneous cardiovascular preparations
Contact us about this page
2.11 Antifibrinolytic drugs and haemostatics
First Line
Second Line
Specialist
Hospital Only
Tranexamic acid
- Tablets 500mg (£4.91 = 60 tablets)
- Solution for injection ampoules 500mg/5ml
- Mouthwash 5% (300ml) (unlicensed preparation)
Indications
- Local fibrinolysis
- Menorrhagia
- Hereditary angioedema
- Epistaxis
Dose
- Local fibrinolysis, 1–1.5g (or 15–25mg/kg) 2–3 times daily
- Menorrhagia (initiated when menstruation has started), 1g 3 times daily for up to 4 days; maximum 4g daily
- Hereditary angioedema, 1–1.5g 2–3 times daily
- Epistaxis, 1g 3 times daily for 7 days
Aprotinin
- Solution for infusion vials 500,000 Kallikrein inactivator units/50ml
Etamsylate
- Solution for injection ampoules 250mg/2ml (unlicensed preparation)
Notes
- For use within Plymouth Hospitals NHS Trust
